New York Attorney General Eric Schneiderman’s office is investigating EpiPen manufacturer Mylan , which may have violated antitrust law in its contracts with local school systems, Schneiderman’s office said Tuesday. Mylan’s price increases on allergic reaction treatment EpiPen prompted public outrage along with lawmaker scrutiny last month. Those price increases could be classified as anti-competitive practices if done “with the intent and effect of limiting lower cost competition,” Schneiderman said. Mylan shares were up 1.0% in early afternoon trade Tuesday. The company’s stock dropped 13.1% over the last three months, compared with a 3.5% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News